Shire

Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Shire utilizing biotech approach to meet unmet ophthalmic needsShire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
6 challenges when changing from a group to private practice
6 challenges when changing from a group to private practiceA little over 18 months ago, I decided to follow my passion and take a leap of faith changing my career. I went from a bustling MD/OD group practice to a private group OD practice and launched the Dry Eye Center of Pennsylvania (PA).
How digital device usage is affecting youthThe time we are spending on digital devices is on the rise, and it’s unlikely to slow down any time soon. With more and more apps, games, and social media options, we have all become more dependent on smartphones, tablets, and other electronic devices.
Dry eye gains importance in glaucoma careNew treatments and greater awareness are making dry eye an even more important part of glaucoma care, according to Richard Lewis, MD, of Sacramento Eye Consultants.
How has ophthalmology changed in 2016?
How has ophthalmology changed in 2016?As the end of the year approaches, we wanted to take a look back at the predictions our Editorial Advisory Board members made for 2016 and see how far we’ve come in the last 12 months.
New dry eye treatment demonstrates rapid onset symptomatic reliefResults from the Phase 3 OPUS-3 trial provide evidence confirming a benefit of lifitegrast ophthalmic solution 5.0% (Xiidra, Shire) for significantly improving dry eye disease-related symptoms, as measured by Eye Dryness Score.
10 highlights from AAO 2016